Venus Remedies Limited, a leading pharmaceutical company known for its commitment to innovation and healthcare excellence, is proud to announce the successful launch of Elores in Ecuador. This significant expansion follows the earlier launches of Elores ln countries like Saudi Arabia, Myanmar, Oman, Tanzania, Ethiopia, and India, marking a momentous stride ln the company's global growth. Additionally, the dossier has also been submitted in around 15 countries for getting the marketing authorizations.

Elores, a cutting-edge antibiotic formulation, has been developed to combat multi-drug-resistant infections, making it an addition to Venus Remedies Limited?s product portfolio. It is a novel patented Antibiotic Adjuvant Entity containing a beta-lactam antibiotic, a beta-Lactamase inhibitor, and an Antibiotic Resistance Breaker (ARB) that work synergistically to rescue antibiotic activity and suppress the emergence of resistance against the antiblotlc. With its proven efficacy against a wide range of bacteria, Elores ls set to revolutionise the treatment of infection and enhance the quality of healthcare in Ecuador.

Elores has garnered widespread acclaim for its unique combination of antibiotics that work synergistically to combat even the most challenging infections. This launch is part of Venus Remedies Limited's ongoing mission to address the global health crisis of antibiotic resistance. Elores was declared the best innovation and received a gold medal under the India Innovation Growth Program in the year 2013.